Cargando…

Ancillary Testing in Lung Cancer Diagnosis

The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubinski, William, Leighl, Natasha B., Tsao, Ming-Sound, Hwang, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259481/
https://www.ncbi.nlm.nih.gov/pubmed/22263108
http://dx.doi.org/10.1155/2012/249082
_version_ 1782221393532813312
author Dubinski, William
Leighl, Natasha B.
Tsao, Ming-Sound
Hwang, David M.
author_facet Dubinski, William
Leighl, Natasha B.
Tsao, Ming-Sound
Hwang, David M.
author_sort Dubinski, William
collection PubMed
description The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may have significant impact on patient management. This review provides an overview of ancillary tests currently used in the pathologic diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics.
format Online
Article
Text
id pubmed-3259481
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32594812012-01-19 Ancillary Testing in Lung Cancer Diagnosis Dubinski, William Leighl, Natasha B. Tsao, Ming-Sound Hwang, David M. Pulm Med Review Article The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may have significant impact on patient management. This review provides an overview of ancillary tests currently used in the pathologic diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics. Hindawi Publishing Corporation 2012 2012-01-04 /pmc/articles/PMC3259481/ /pubmed/22263108 http://dx.doi.org/10.1155/2012/249082 Text en Copyright © 2012 William Dubinski et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dubinski, William
Leighl, Natasha B.
Tsao, Ming-Sound
Hwang, David M.
Ancillary Testing in Lung Cancer Diagnosis
title Ancillary Testing in Lung Cancer Diagnosis
title_full Ancillary Testing in Lung Cancer Diagnosis
title_fullStr Ancillary Testing in Lung Cancer Diagnosis
title_full_unstemmed Ancillary Testing in Lung Cancer Diagnosis
title_short Ancillary Testing in Lung Cancer Diagnosis
title_sort ancillary testing in lung cancer diagnosis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259481/
https://www.ncbi.nlm.nih.gov/pubmed/22263108
http://dx.doi.org/10.1155/2012/249082
work_keys_str_mv AT dubinskiwilliam ancillarytestinginlungcancerdiagnosis
AT leighlnatashab ancillarytestinginlungcancerdiagnosis
AT tsaomingsound ancillarytestinginlungcancerdiagnosis
AT hwangdavidm ancillarytestinginlungcancerdiagnosis